Ina podcast accompanying the journal articles, Dr. Donald S. Baim, chief medical and scientific officer of Boston Scientific, called the label "artificially narrow" based on recent trial data.
Based on recent trial findings that demonstrate a difference in cardiovascular morbidity between β-blocker and ACEi-based therapy [ 26], we also stratified by β-blocker medication status (Additional file 1: Table S7) and RAAS blockade use (Additional file 1: Table S8).
This biweekly (every 2 weeks) chemotherapy schedule was based on recent trials with proper dosage adjustment and a successful outcome (Cardenal et al, 2003; Negoro et al, 2003).
In addition to these disappointing results in terms of rehabilitation delivery, data are currently lacking, based on recent trials [ 10, 11], to guide timing and quantity of nutritional delivery, another important factor in skeletal muscle homeostasis [ 12].
Based on recent clinical trial data, the US Food and Drug Administration have changed the labelling of all statins to include 'an effect of statins on incident diabetes and increases in haemoglobin A1c and/or FPG'.
But she added that she was hopeful based on recent clinical trials showing that some patients improved after being treated with drugs directed at the vascular endothelial growth factor.
Based on recent clinical trials, rituximab, the anti-CD20 monoclonal antibody, can be used as an alternative to cyclophosphamide.
These guidelines were based on recent clinical trials that showed statistically significant statin-induced relative risk reductions (RRR) in cardiovascular events.
Based on recent clinical trials, basic physiology and evolution, the acute phase may be a period when a reduced-nonprotein-calorie, high-protein delivery (1.5 to 2.0 g/kg/day) may be optimal.
Although gemcitabine-based chemotherapy may be the preferred treatment based on recent phase III trials, it is not evident whether gemcitabine surpasses fluoropyrimidine in terms of efficacy (Kim et al, 2008a).
This has recently been demonstrated within nephrology by the evolution of anemia management in patients with CKD based on recent randomized clinical trials of erythropoiesis-stimulating agents [ 19- 21], emphasizing the importance of well-conducted trials in informing national guidelines and influencing provider perceptions of their credibility.
